Additionally, since the APOBEC mutational signature (SBS2 and SBS13) has been proposed as a biomarker for ICI response in some cancers17,18, we used more than 2000 ICI-treated samples19–21, finding AID-related fraction of mutations as an independent prognostic value to ICI after adjusting by tumor mutational burden (TMB) and APOBEC signature. Here, AICDA is linked to neoplasm.